SAGE Therapeutics (SAGE) Tops Q3 EPS by 1c

SAGE Therapeutics (NASDAQ: SAGE) reported Q3 EPS of ($1.53), $0.01 better than the analyst estimate of ($1.54). Revenue for the quarter came in at $11.87 million versus the consensus estimate of $10.8 million.

For earnings history and earnings-related data on SAGE Therapeutics (SAGE) click here.

You May Also Be Interested In

• Musalem: strong growth and investment influencing bond market - CNBC
• Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
• Nvidia plans China chip shipments with export-compliant AI processor - The Information